Peretti G
Divisione Ortopedia e Traumatologia, Ospedale San Gerardo-Monza (Milano).
Minerva Med. 1996 Apr;87(4):155-60.
We tested the therapeutic response of osteoarthrosis subjects to 30 mg piroxicam cinnamate (Sinartrol). The double-blind study was conducted in 2 homogeneous groups of 30 patients each treated with piroxicam cinnamate one 30-mg tablet twice daily for 2 days followed by 1 tablet daily for further 13 days and with piroxicam cinnamate 20 mg tablets (according to the same posologic scheme) respectively. The results obtained demonstrate the efficacy of this new piroxicam cinnamate formulation which led to a significant clinical improvement, already evident after 2 days of treatment and even more evident at the end of therapy. Patients compliance to treatment was good and side effects were scarce and spontaneously subsiding.
我们测试了骨关节炎患者对30毫克肉桂酸吡罗昔康(Sinartrol)的治疗反应。这项双盲研究在两组同质患者中进行,每组30例,分别接受肉桂酸吡罗昔康治疗,一组每日两次服用1片30毫克片剂,持续2天,随后每日1片,再持续13天;另一组服用20毫克肉桂酸吡罗昔康片剂(按照相同的给药方案)。所获得的结果证明了这种新型肉桂酸吡罗昔康制剂的疗效,治疗2天后临床症状即有显著改善,治疗结束时更为明显。患者对治疗的依从性良好,副作用较少且可自行消退。